Similasan Settles $3.57M Lawsuit Over FDA Compliance and Safety Claims

Similasan Corp., a Swiss company known for its homeopathic eye drops, has agreed to a $3.57 million settlement after being accused of selling its products as drugs without U.S. Food and Drug Administration (FDA) approval and failing to meet necessary safety standards.

Similasan and plaintiffs David Plowden, Mario Ortega and Kamille Faye Vinluan-Jularbal filed the proposed settlement on Nov. 6 in a Colorado federal court. 

Read more at Top Class Actions.